Essential role of calmodulin in RyR inhibition by dantrolene

Molecular Pharmacology

Volumn 88, Issue 1, 2015, Pages 57-63

  Oo, Ye Win ^a   Gomez Hurtado, Nieves ^b   Walweel, Kafa ^a   Van Helden, Dirk F ^a   Imtiaz, Mohammad S ^a   Knollmann, Bjorn C ^b   Laver, Derek R ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALMODULIN; DANTROLENE; RYANODINE RECEPTOR 1; RYANODINE RECEPTOR 2; CALCIUM; MUSCLE RELAXANT AGENT; RYANODINE RECEPTOR;

ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HEART MUSCLE; HISTOGRAM; IC50; LIPID BILAYER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RABBIT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; DRUG EFFECTS; MALIGNANT HYPERTHERMIA; METABOLISM; MOUSE; SHEEP;

ANIMALS; CALCIUM; CALMODULIN; DANTROLENE; MALIGNANT HYPERTHERMIA; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MYOCYTES, CARDIAC; NEUROMUSCULAR AGENTS; RABBITS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SHEEP;

EID: 84940192882     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.097691     Document Type: Article

References (45)

1. Balshaw DM, Xu L, Yamaguchi N, Pasek DA, and Meissner G (2001) Calmodulin binding and inhibition of cardiac muscle calcium release channel (ryanodine receptor). J Biol Chem 276:20144-20153.
2. Buyukokuroglu ME, Gulcin I, Oktay M, and Kufrevioglu OI (2001) In vitro antioxidant properties of dantrolene sodium. Pharmacol Res 44:491-494.
3. Buyukokuroglu ME, Taysi S, Polat F, and Gocer F (2002) Mechanism of the beneficial effects of dantrolene sodium on ethanol-induced acute gastric mucosal injury in rats. Pharmacol Res 45:421-425.
4. Cherednichenko G, Ward CW, Feng W, Cabrales E, Michaelson L, Samso M, López JR, Allen PD, and Pessah IN (2008) Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. Mol Pharmacol 73:1203-1212.
5. Chou CC, Wen MS, Lee HL, Chang PC, Wo HT, Yeh SJ, and Wu D (2014) Dantrolene suppresses ventricular ectopy and arrhythmogenicity with acute myocardial infarction in a langendorff-perfused pacing-induced heart failure rabbit model. J Cardiovasc Electrophysiol 25:431-439.
6. Diaz-Sylvester PL, Porta M, and Copello JA (2008) Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP. Am J Physiol Cell Physiol 294:C1103-C1112.
7. Flewellen EH, Nelson TE, Jones WP, Arens JF, and Wagner DL (1983) Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 59:275-280.
8. Fruen BR, Mickelson JR, and Louis CF (1997) Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem 272:26965-26971.
9. Galimberti ES and Knollmann BC (2011) Efficacy and potency of class I anti-arrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 51:760-768.
10. Guo T, Fruen BR, Nitu FR, Nguyen TD, Yang Y, Cornea RL, and Bers DM (2011) FRET detection of calmodulin binding to the cardiac RyR2 calcium release channel. Biophys J 101:2170-2177.
11. Hainaut K and Desmedt JE (1974) Effect of dantrolene sodium on calcium movements in single muscle fibres. Nature 252:728-730.
12. Huang X, Liu Y, Wang R, Zhong X, Liu Y, Koop A, Chen SR, Wagenknecht T, and Liu Z (2013) Two potential calmodulin-binding sequences in the ryanodine receptor contribute to a mobile, intra-subunit calmodulin-binding domain. J Cell Sci 126:4527-4535.
13. Hwang HS, Nitu FR, Yang Y, Walweel K, Pereira L, Johnson CN, Faggioni M, Chazin WJ, Laver D, and George AL, Jr et al. (2014) Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants. Circ Res 114:1114-1124.
14. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, Dorn T, Ruppenthal S, Pfeiffer S, and Goedel A et al. (2012) Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 4:180-191.
15. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Ettensohn K, Knollmann BE, Horton KD, Weissman NJ, and Holinstat I et al. (2006) Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 116:2510-2520.
16. Kobayashi S, Bannister ML, Gangopadhyay JP, Hamada T, Parness J, and Ikemoto N (2005) Dantrolene stabilizes domain interactions within the ryanodine receptor. J Biol Chem 280:6580-6587.
17. Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M, Xu X, Uchinoumi H, Okuda S, and Yamamoto T et al. (2009) Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol 53:1993-2005.
18. Kobayashi S, Yano M, Uchinoumi H, Suetomi T, Susa T, Ono M, Xu X, Tateishi H, Oda T, and Okuda S et al. (2010) Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model. Circ J 74:2579-2584.
19. Laver DR, Roden LD, Ahern GP, Eager KR, Junankar PR, and Dulhunty AF (1995) Cytoplasmic Ca2+ inhibits the ryanodine receptor from cardiac muscle. J Membr Biol 147:7-22.
20. Marks AR, Marx SO, and Reiken S (2002) Regulation of ryanodine receptors via macromolecular complexes: a novel role for leucine/isoleucine zippers. Trends Cardiovasc Med 12:166-170.
21. Maxwell JT, Domeier TL, and Blatter LA (2012) Dantrolene prevents arrhythmogenic Ca2+ release in heart failure. Am J Physiol Heart Circ Physiol 302:H953-H963.
22. McCarthy TV, Healy JM, Heffron JJ, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, and Johnson K (1990) Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 343:562-564.
23. Monnier N, Procaccio V, Stieglitz P, and Lunardi J (1997) Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 60:1316-1325.
24. Nelson TE, Lin M, Zapata-Sudo G, and Sudo RT (1996) Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications. Anesthesiology 84:1368-1379.
25. O'Neill ER, Sakowska MM, and Laver DR (2003) Regulation of the calcium release channel from skeletal muscle by suramin and the disulfonated stilbene derivatives DIDS, DBDS, and DNDS. Biophys J 84:1674-1689.
26. Parness J and Palnitkar SS (1995) Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. J Biol Chem 270:18465-18472.
27. Paul-Pletzer K, Palnitkar SS, Jimenez LS, Morimoto H, and Parness J (2001) The skeletal muscle ryanodine receptor identified as a molecular target of [3H]azidodantrolene by photoaffinity labeling. Biochemistry 40:531-542.
28. Paul-Pletzer K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, and Parness J (2002) Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 277:34918-34923.
29. Paul-Pletzer K, Yamamoto T, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Ma J, and Parness J (2005) Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. Biochem J 387:905-909.
30. Podranski T, Bouillon T, Schumacher PM, Taguchi A, Sessler DI, and Kurz A (2005) Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? Anesth Analg 101:1695-1699.
31. Salata JJ, Wasserstrom JA, and Jalife J (1983) Dantrolene sodium: effects on isolated cardiac tissues. J Mol Cell Cardiol 15:233-243.
32. Sigworth FJ and Sine SM (1987) Data transformations for improved display and fitting of single-channel dwell time histograms. Biophys J 52:1047-1054.
33. Suetomi T, Yano M, Uchinoumi H, Fukuda M, Hino A, Ono M, Xu X, Tateishi H, Okuda S, and Doi M et al. (2011) Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca2+release leading to catecholaminergic polymorphic ventricular tachycardia. Circulation 124:682-694.
34. Szentesi P, Collet C, Sárközi S, Szegedi C, Jona I, Jacquemond V, Kovács L, and Csernoch L (2001) Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers. J Gen Physiol 118:355-375.
35. Tinker A and Williams AJ (1993) Charged local anesthetics block ionic conduction in the sheep cardiac sarcoplasmic reticulum calcium release channel. Biophys J 65:852-864.
36. Tripathy A, Xu L, Mann G, and Meissner G (1995) Calmodulin activation and inhibition of skeletal muscle Ca2+ release channel (ryanodine receptor). Biophys J 69:106-119.
37. Tsushima RG, Kelly JE, and Wasserstrom JA (2002) Subconductance activity induced by quinidine and quinidinium in purified cardiac sarcoplasmic reticulum calcium release channels. J Pharmacol Exp Ther 301:729-737.
38. Uchinoumi H, Yano M, Suetomi T, Ono M, Xu X, Tateishi H, Oda T, Okuda S, Doi M, and Kobayashi S et al. (2010) Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ Res 106:1413-1424.
39. Ucuncu H, Taysi S, Aktan B, Buyukokuroglu ME, and Elmastas M (2005) Effect of dantrolene on lipid peroxidation, lutathione and glutathione-dependent enzyme activities in experimental otitis media with effusion in guinea pigs. Hum Exp Toxicol 24:567-571.
40. Wagner LE, 2nd, Groom LA, Dirksen RT, and Yule DI (2014) Characterization of ryanodine receptor type 1 single channel activity using "on-nucleus" patch clamp. Cell Calcium 56:96-107.
41. Xu L, Jones R, and Meissner G (1993) Effects of local anesthetics on single channel behavior of skeletal muscle calcium release channel. J Gen Physiol 101:207-233.
42. Yang Y, Guo T, Oda T, Chakraborty A, Chen L, Uchinoumi H, Knowlton AA, Fruen BR, Cornea RL, and Meissner G et al. (2014) Cardiac myocyte Z-line calmodulin is mainly RyR2-bound, and reduction is arrhythmogenic and occurs in heart failure. Circ Res 114:295-306.
43. Yano M (2005) [Abnormal ryanodine receptor function in heart failure]. Nihon Yakurigaku Zasshi 126:372-376.
44. Zamiri N, Massé S, Ramadeen A, Kusha M, Hu X, Azam MA, Liu J, Lai PF, Vigmond EJ, and Boyle PM et al. (2014) Dantrolene improves survival after ventricular fibrillation by mitigating impaired calcium handling in animal models. Circulation 129:875-885.
45. Zhao F, Li P, Chen SR, Louis CF, and Fruen BR (2001) Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 276:13810-13816.